Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;128(12):1580-1588.
doi: 10.1007/s11547-023-01721-7. Epub 2023 Sep 20.

Stereotactic reirradiation with CyberknifeR for locally recurrent prostate cancer, long-term toxicity and clinical outcomes from a monocentric cohort

Giulio Francolini  1 , Maria Grazia Carnevale  2 , Vanessa Di Cataldo  3 , Mauro Loi  3 , Beatrice Detti  3 , Carolina Orsatti  2 , Luisa Caprara  2 , Niccolò Bertini  2 , Victoria Lorenzetti  2 , Emanuela Olmetto  3 , Carlotta Becherini  3 , Luca Visani  4 , Viola Salvestrini  4 , Gabriele Simontacchi  3 , Daniela Greto  3 , Pierluigi Bonomo  3 , Raffaela Doro  4 , Laura Masi  4 , Isacco Desideri  2 , Icro Meattini  2 , Sergio Serni  5   6 , Lorenzo Livi  2
Affiliations

Stereotactic reirradiation with CyberknifeR for locally recurrent prostate cancer, long-term toxicity and clinical outcomes from a monocentric cohort

Giulio Francolini et al. Radiol Med. 2023 Dec.

Abstract

Purpose: Up to 47% of patients with localized prostate cancer (PCa) treated with radiotherapy (EBRT) eventually develop local recurrence. To date, no clear consensus exists on optimal management. A growing body of interest supports the use of stereotaxic re-irradiation (rSBRT), with promising oncological outcomes and low toxicity profile. We collected a single-center case series of locally recurrent PCa who underwent re-irradiation after a previous course of postoperative or definitive radiotherapy.

Methods and materials: Data from 101 patients treated at our institution for locally recurrent PCa from June 2012 to June 2021 were retrospectively collected. Patients underwent rSBRT with CyberKnife system (Accuray Inc., Sunnyvale, CA, USA), delivered to intraprostatic or macroscopic recurrences within the prostate bed, for a total dose of 30 Gy in 5 fractions.

Results: All patients received prior EBRT. The median EQD2 total dose was 75.0 Gy (range, 60-80 Gy). Thirty-two (32%) patients were receiving androgen deprivation therapy (ADT) after prior biochemical recurrence. After a median follow-up of 57.8 months, BR occurred in 55 patients (54.5%), with a median BR-free survival (BRFS) of 40.4 months (95% C.I. 34.3-58.3). Thirty-two patients (31.7%) developed metastatic disease, with a median metastasis-free survival (MFS) not reached. PSA ≥ 2.5 ng/ml and ADT were associated with worst BRFS (26.06 vs. 39.3 months, p = 0.03 and 22.7 vs. 27 months, p = 0.01, respectively). Castration-resistant status and ADT were found to be predictive of worst MFS (34.1 vs. 50.5 months, p = 0.02 and 33.5 vs. 53.1 months, p = 0.002, respectively). Concomitant ADT was confirmed as an independent factor for MFS (HR 4.8, 95% CI 1.5-10.6, p = 0.007). No grade > /2 adverse were recorded.

Conclusions: After almost 5 years of follow-up, with a median BRFS of 40.4 months and no grade ≥ 2 AEs, CyberknifeR rSBRT proved effective and safe in a cohort of 101 patients affected by locally recurrent PCa.

Keywords: Cyberknife; Prostate cancer; Reirradiation.

PubMed Disclaimer

References

    1. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR, Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) (2008) Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 112(2):307–314. https://doi.org/10.1002/cncr.23161 - DOI - PubMed
    1. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR (1996) Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47(2):225–231. https://doi.org/10.1016/S0090-4295(99)80421-X - DOI - PubMed
    1. Saleem MD, Sanders H, Abu El Naser M, El-Galley R (1998) Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 51(2):283–286. https://doi.org/10.1016/s0090-4295(97)00509-8 - DOI - PubMed
    1. Jereczek-Fossa BA, Marvaso G, Zaffaroni M, Gugliandolo SG, Zerini D, Corso F, Gandini S, Alongi F, Bossi A, Cornford P, De Bari B, Fonteyne V, Hoskin P, Pieters BR, Tree AC, Arcangeli S, Fuller DB, Franzese C, Hannoun-Levi JM, Janoray G, on the behalf of the European Society for Radiotherapy, Oncology Advisory Committee on Radiation Oncology Practice (ESTRO ACROP) (2021) Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: an ESTRO ACROP Delphi consensus. Cancer Treat Rev, 98:102206. https://doi.org/10.1016/j.ctrv.2021.102206
    1. Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, Christidis D, Bolton D, Hofman MS, Lawrentschuk N, Murphy DG (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77(4):403–417. https://doi.org/10.1016/j.eururo.2019.01.049 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources